Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2 Step ATG for Prevention of Acute GVHD Post Stem Cell Transplant
NCT06265584Phase 2Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Apr 2025
- Primary completion
- Aug 2028
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antithymocyte globulin rabbit in graft-versus-host disease (GVHD), sponsored by University of Alabama at Birmingham. Primary endpoint: GVHD, Relapse-Free Survival at 1 year. Started Apr 2025; status: recruiting.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06265584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06265584.